Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi all
So some of you would have seen this but this is how the government will decide who gets that 5 billon contract from the NHs. Basically they are seeing how the test cope in real situations. Of course with our new range of test kits and a mobile test kit being launched we would be ideally placed.
Regards
Bramley 1967
AZ are helping Novacyt with progressing the tests. AZ are working with Novacyt to use saliva samples instead of the normal swabs for their employees as easier to use. As GGGG and I have already said the PCR test can already be used with saliva samples but do not currently have approved. I imagine the roll out in July with AZ employees will go towards data collection sent in for approval of using saliva samples with Novacyt PCR test however this is yet to be confirmed. Hopefully that clears that up. Check my previous posting history I’m an AZ employee. This company will be worth a huge amount more come Q4 and 2021.
thanks for the link that explains it better than there letter ,2 of my family are on the programme for the swab and saliva test. so it appears they will be following up with an antibody test if tested positive. so they are trying to gel the test
ing for data together . intriqued on the saliva test without ramping?
Bramley good info. I am very confident with primerdesign performing well. A few reasons. 1) score highest on findx (who approval site) 2) we got the best scoring from PHE when they did recent evaluation. 3) We are probably the most approved pcr test globally have been evaluated by so many health trusts. 1st in France 1st in uk. One of first in US. 2nd for WHO. Used so heavily in Germany. One of first in India etc. 4) the US fda eua re evaluated tests removed a shed loads and yep we were kept with fda approval.
Ps AZ and novacyt have saliva covered to ;)
https://www.nihr.ac.uk/news/new-13-million-national-research-programme-to-evaluate-coronavirus-tests-in-hospitals-general-practices-and-care-homes/25111
Its really important we perform well in these tests as its how we will be accepted onto the NHS going forward. I have no doubt we will as we keep on evolving. This looks like a lengthy progress but will keep checking it they publish a list of who they are looking at.
regards
Bramley1967
Hi All
I have been investigating what method the NHS will use to evaluate the tests that will be used for the new 5 billion pound project and have found this the new Condor program
First mention is in here and shows who is on the board and what they are looking at
The program will be led by the Manchester University NHS Foundation Trust, the University of Manchester and the University of Oxford in collaboration with four NIHR Medtech and IVD Co-operatives as well as the University of Nottingham and the National Measurement Laboratory. It will also collaborate with the National Institute for Health and Care Excellence to assess individual tests’ benefits.
“For example, we’re going to look at tests that use different approaches to collecting samples other than the nose and throat swabs, which are uncomfortable,” said Richard Body, professor of emergency medicine at the University of Manchester. “Some tests in development at the moment measure the virus in saliva, which is much easier and more convenient to collect.”
secondly I found this
http://www.newcastle.mic.nihr.ac.uk/condor-platform
The NIHR Newcastle In Vitro Diagnostics Co-operative are part of a national partnership awarded ÂŁ1.3M to robustly evaluate new COVID-19 tests
Published: 24/06/20
A key part of our response to the COVID-19 pandemic is the development of accurate tests to: identify individuals infected with SARS-Cov-2 (the virus causing COVID-19); monitor the progression of the disease and find out whether individuals have developed immunity. The life science sector has responded swiftly to this demand, developing over 240 CE marked tests related to COVID-19. Some of these tests have the potential to increase the speed and convenience of testing. However, due to the urgency of the situation, many of these tests have received emergency use authorisation based on limited preliminary data. There is a need to rigorously evaluate the performance of these tests, particularly in a real-life context, so we can introduce the most effective and reliable new tests as soon as possible.
The NIHR Newcastle In Vitro Diagnostics Co-operative (Newcastle MIC), a partnership between Newcastle Upon Tyne Hospitals NHS Foundation Trust and Newcastle University, have received funding from the National Institute for Health Research (NIHR), UK Research and Innovation, Asthma UK and British Lung Foundation to form the agile COVID-19 National DiagnOstic Research and Evaluation Platform (CONDOR) with partners across England who are fellow experts in evaluating new diagnostic tests. The platform has been recognised as nationally prioritised by the Urgent Public Health Panel and will allow us to have a co-ordinated approach to rapidly and robustly assessing new tests for COVID-19 including ones which have been prioritised by the government and its scientific advisors within the New Tests Approvals Group and Viral Detection Tests Approvals Group
This needs more investigation team?